Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Valion Bio, Inc.VBIO · Entity 8459 | COO & CFO | September 18, 2026 | September 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Valion Bio, Inc.
Report date September 18, 2026 · Filed September 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29 |
Reported balance
After 2026-09-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-18 · Exercise / conversion · Acquired 4 · Balance 29 F1: Each Restricted Stock Unit is convertible into one share of Common Stock. F3: Fifty percent (50%) of the Restricted Stock Units vested upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date. |
| Common StockSEC Table I · non-derivative | Direct | 27 |
Reported balance
After 2026-09-18 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-18 · Tax withholding · Disposed 2 · Balance 27 F2: The Reporting Person forfeited 2 shares of Common Stock upon vesting and settlement of 4 outstanding Restricted Stock Units to cover tax withholdings, using the market price of the Issuer's Common Stock at the time of forfeiture. F4: These numbers have been adjusted to reflect the reverse stock split of the Common Stock of Valion Bio, Inc., which underwent a reverse stock split at a ratio of 1-for-25 on August 31, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 19 |
Reported balance
After 2026-09-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-18 · Exercise / conversion · Disposed 4 · Balance 19 F1: Each Restricted Stock Unit is convertible into one share of Common Stock. F3: Fifty percent (50%) of the Restricted Stock Units vested upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date. F4: These numbers have been adjusted to reflect the reverse stock split of the Common Stock of Valion Bio, Inc., which underwent a reverse stock split at a ratio of 1-for-25 on August 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit is convertible into one share of Common Stock.
F2: The Reporting Person forfeited 2 shares of Common Stock upon vesting and settlement of 4 outstanding Restricted Stock Units to cover tax withholdings, using the market price of the Issuer's Common Stock at the time of forfeiture.
F3: Fifty percent (50%) of the Restricted Stock Units vested upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date.
F4: These numbers have been adjusted to reflect the reverse stock split of the Common Stock of Valion Bio, Inc., which underwent a reverse stock split at a ratio of 1-for-25 on August 31, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Resonant Inc
Report date March 28, 2022 · Filed March 28, 2022
Section 16 reporting ended · disclosed 2022-03-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-03-28 transaction · row 1
1 source rowRow 1 · 2022-03-28 · Other · Disposed 170,568 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectBy Ms. Wolf's daughter | 0 |
Reported balance
After 2022-03-28 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2022-03-28 · Other · Disposed 40 · Balance 0 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.20 · Expires 2024-06-30 | Direct | 0 |
Reported balance
After 2022-03-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-28 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: In connection with the Agreement and Plan of Merger, dated February 14, 2022, by and among Murata Electronics North America, Inc., PJ Cosmos Acquisition Company, Inc. and Resonant Inc. (the "Merger Agreement"), this stock option, which is fully vested, was cancelled in the merger. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.07 · Expires 2026-08-08 | Direct | 0 |
Reported balance
After 2022-03-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-03-28 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: In connection with the Agreement and Plan of Merger, dated February 14, 2022, by and among Murata Electronics North America, Inc., PJ Cosmos Acquisition Company, Inc. and Resonant Inc. (the "Merger Agreement"), this stock option, which is fully vested, was cancelled in the merger. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 · Expires 2027-02-02 | Direct | 0 |
Reported balance
After 2022-03-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-03-28 · Disposition to issuer · Disposed 15,319 · Balance 0 F2: In connection with the Merger Agreement, this stock option, which is fully vested, was assumed and converted into a right of the holder to receive, no later than the first payroll date that occurs at least five business days after the closing of the merger, an amount in cash equal to the excess of the per share merger consideration of $4.50 over the exercise price per share of the common stock subject to the stock option multiplied by the total number of shares of common stock subject to such stock option immediately prior to the merger. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.51 · Expires 2027-08-07 | Direct | 0 |
Reported balance
After 2022-03-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-03-28 · Disposition to issuer · Disposed 6,688 · Balance 0 F1: In connection with the Agreement and Plan of Merger, dated February 14, 2022, by and among Murata Electronics North America, Inc., PJ Cosmos Acquisition Company, Inc. and Resonant Inc. (the "Merger Agreement"), this stock option, which is fully vested, was cancelled in the merger. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.62 · Expires 2027-11-06 | Direct | 0 |
Reported balance
After 2022-03-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-03-28 · Disposition to issuer · Disposed 4,808 · Balance 0 F1: In connection with the Agreement and Plan of Merger, dated February 14, 2022, by and among Murata Electronics North America, Inc., PJ Cosmos Acquisition Company, Inc. and Resonant Inc. (the "Merger Agreement"), this stock option, which is fully vested, was cancelled in the merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-03-28 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-03-28 · Disposition to issuer · Disposed 6,931 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Resonant Inc. common stock. F4: In connection with the Merger Agreement, these restricted stock units, which provided for vesting on December 1, 2022, were assumed and converted into a right of the holder to receive upon settlement an amount in cash equal to the per share merger consideration of $4.50 multiplied by the number of shares of common stock subject to such restricted stock units immediately prior to the merger. Upon the termination of the holder's employment with Resonant Inc. immediately following consummation of the merger, these assumed restricted stock units became fully vested and will be settled in cash. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-03-28 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-03-28 · Disposition to issuer · Disposed 20,787 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Resonant Inc. common stock. F5: In connection with the Merger Agreement, these restricted stock units, which provided for vesting of 10,394 shares on December 1, 2022 and 10,393 shares on December 1, 2023, were assumed and converted into a right of the holder to receive upon settlement an amount in cash equal to the per share merger consideration of $4.50 multiplied by the number of shares of common stock subject to such restricted stock units immediately prior to the merger. Upon the termination of the holder's employment with Resonant Inc. immediately following consummation of the merger, these assumed restricted stock units became fully vested and will be settled in cash. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-03-28 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-03-28 · Disposition to issuer · Disposed 29,577 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Resonant Inc. common stock. F6: In connection with the Merger Agreement, these restricted stock units, which provided for vesting of 9,859 shares on each of December 1, 2022, December 1, 2023, and December 1, 2024, were assumed and converted into a right of the holder to receive upon settlement an amount in cash equal to the per share merger consideration of $4.50 multiplied by the number of shares of common stock subject to such restricted stock units immediately prior to the merger. Upon the termination of the holder's employment with Resonant Inc. immediately following consummation of the merger, these assumed restricted stock units became fully vested and will be settled in cash. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-03-28 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-03-28 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Resonant Inc. common stock. F7: In connection with the Merger Agreement, these restricted stock units, which provided for vesting of 12,500 shares on each of December 1, 2022 and December 1, 2023, were assumed and converted into a right of the holder to receive upon settlement an amount in cash equal to the per share merger consideration of $4.50 multiplied by the number of shares of common stock subject to such restricted stock units immediately prior to the merger. Upon the termination of the holder's employment with Resonant Inc. immediately following consummation of the merger, these assumed restricted stock units became fully vested and will be settled in cash. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-03-28 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-03-28 · Disposition to issuer · Disposed 53,244 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Resonant Inc. common stock. F8: In connection with the Merger Agreement, these restricted stock units, which provided for vesting of 13,111 shares on each of December 1, 2022, December 1, 2023, December 1, 2024, and December 1, 2025, were assumed and converted into a right of the holder to receive upon settlement an amount in cash equal to the per share merger consideration of $4.50 multiplied by the number of shares of common stock subject to such restricted stock units immediately prior to the merger. Upon the termination of the holder's employment with Resonant Inc. immediately following consummation of the merger, these assumed restricted stock units became fully vested and will be settled in cash. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the Agreement and Plan of Merger, dated February 14, 2022, by and among Murata Electronics North America, Inc., PJ Cosmos Acquisition Company, Inc. and Resonant Inc. (the "Merger Agreement"), this stock option, which is fully vested, was cancelled in the merger.
F2: In connection with the Merger Agreement, this stock option, which is fully vested, was assumed and converted into a right of the holder to receive, no later than the first payroll date that occurs at least five business days after the closing of the merger, an amount in cash equal to the excess of the per share merger consideration of $4.50 over the exercise price per share of the common stock subject to the stock option multiplied by the total number of shares of common stock subject to such stock option immediately prior to the merger.
F3: Each restricted stock unit represents a contingent right to receive one share of Resonant Inc. common stock.
F4: In connection with the Merger Agreement, these restricted stock units, which provided for vesting on December 1, 2022, were assumed and converted into a right of the holder to receive upon settlement an amount in cash equal to the per share merger consideration of $4.50 multiplied by the number of shares of common stock subject to such restricted stock units immediately prior to the merger. Upon the termination of the holder's employment with Resonant Inc. immediately following consummation of the merger, these assumed restricted stock units became fully vested and will be settled in cash.
F5: In connection with the Merger Agreement, these restricted stock units, which provided for vesting of 10,394 shares on December 1, 2022 and 10,393 shares on December 1, 2023, were assumed and converted into a right of the holder to receive upon settlement an amount in cash equal to the per share merger consideration of $4.50 multiplied by the number of shares of common stock subject to such restricted stock units immediately prior to the merger. Upon the termination of the holder's employment with Resonant Inc. immediately following consummation of the merger, these assumed restricted stock units became fully vested and will be settled in cash.
F6: In connection with the Merger Agreement, these restricted stock units, which provided for vesting of 9,859 shares on each of December 1, 2022, December 1, 2023, and December 1, 2024, were assumed and converted into a right of the holder to receive upon settlement an amount in cash equal to the per share merger consideration of $4.50 multiplied by the number of shares of common stock subject to such restricted stock units immediately prior to the merger. Upon the termination of the holder's employment with Resonant Inc. immediately following consummation of the merger, these assumed restricted stock units became fully vested and will be settled in cash.
F7: In connection with the Merger Agreement, these restricted stock units, which provided for vesting of 12,500 shares on each of December 1, 2022 and December 1, 2023, were assumed and converted into a right of the holder to receive upon settlement an amount in cash equal to the per share merger consideration of $4.50 multiplied by the number of shares of common stock subject to such restricted stock units immediately prior to the merger. Upon the termination of the holder's employment with Resonant Inc. immediately following consummation of the merger, these assumed restricted stock units became fully vested and will be settled in cash.
F8: In connection with the Merger Agreement, these restricted stock units, which provided for vesting of 13,111 shares on each of December 1, 2022, December 1, 2023, December 1, 2024, and December 1, 2025, were assumed and converted into a right of the holder to receive upon settlement an amount in cash equal to the per share merger consideration of $4.50 multiplied by the number of shares of common stock subject to such restricted stock units immediately prior to the merger. Upon the termination of the holder's employment with Resonant Inc. immediately following consummation of the merger, these assumed restricted stock units became fully vested and will be settled in cash.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2026 Filed Sep 24, 2026 20:45 UTC | Valion Bio, Inc. VBIO · Entity 8459 | Exercise / conversionRestricted Stock Units · Derivative | 4 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-007396 · ownership.xml · derivative · entry 3 Wolf Lisa G · CIK 0001861556 · COO & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19 Underlying: Common Stock · 4 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit is convertible into one share of Common Stock. F3 · derivative.exercise_date: Fifty percent (50%) of the Restricted Stock Units vested upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: Fifty percent (50%) of the Restricted Stock Units vested upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date. F4 · balance_after: These numbers have been adjusted to reflect the reverse stock split of the Common Stock of Valion Bio, Inc., which underwent a reverse stock split at a ratio of 1-for-25 on August 31, 2026. Read SEC document |
| September 18, 2026 Filed Sep 24, 2026 20:45 UTC | Valion Bio, Inc. VBIO · Entity 8459 | Tax withholdingCommon Stock | 2 | $2.12 | $4.24 |
DisclosureSEC source: 0001683168-26-007396 · ownership.xml · nonDerivative · entry 2 Wolf Lisa G · CIK 0001861556 · COO & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27 F2 · kind: The Reporting Person forfeited 2 shares of Common Stock upon vesting and settlement of 4 outstanding Restricted Stock Units to cover tax withholdings, using the market price of the Issuer's Common Stock at the time of forfeiture. F4 · balance_after: These numbers have been adjusted to reflect the reverse stock split of the Common Stock of Valion Bio, Inc., which underwent a reverse stock split at a ratio of 1-for-25 on August 31, 2026. Read SEC document |
| September 18, 2026 Filed Sep 24, 2026 20:45 UTC | Valion Bio, Inc. VBIO · Entity 8459 | Exercise / conversionCommon Stock | 4 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-26-007396 · ownership.xml · nonDerivative · entry 1 Wolf Lisa G · CIK 0001861556 · COO & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit is convertible into one share of Common Stock. F3 · balance_after: Fifty percent (50%) of the Restricted Stock Units vested upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date. Read SEC document |
| June 18, 2026 Filed Jun 18, 2026 20:30 UTC | Valion Bio, Inc. VBIO · Entity 8459 | Exercise / conversionRestricted Stock Units · Derivative | 92 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-004970 · ownership.xml · derivative · entry 2 Wolf Lisa G · CIK 0001861556 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 551 Underlying: Common Stock · 92 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit is convertible into one share of Common Stock. F2 · derivative.exercise_date: Fifty percent (50%) of the Restricted Stock Units vested upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date. F2 · derivative.expiration_date: Fifty percent (50%) of the Restricted Stock Units vested upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date. Read SEC document |
| June 18, 2026 Filed Jun 18, 2026 20:30 UTC | Valion Bio, Inc. VBIO · Entity 8459 | Exercise / conversionCommon Stock | 92 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-26-004970 · ownership.xml · nonDerivative · entry 1 Wolf Lisa G · CIK 0001861556 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit is convertible into one share of Common Stock. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 01:14 UTC | Valion Bio, Inc. TIVC · Entity 8459 | Exercise / conversionRestricted Stock Units · Derivative | 92 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-002034 · ownership.xml · derivative · entry 2 Wolf Lisa G · CIK 0001861556 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 643 Underlying: Common Stock · 92 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit is convertible into one share of Common Stock. F3 · derivative.exercise_date: Fifty percent (50%) of the Restricted Stock Units vested upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: Fifty percent (50%) of the Restricted Stock Units vested upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date. F2 · balance_after: These numbers have been adjusted to reflect the reverse stock split of the common stock of Tivic Health Systems, Inc., which underwent a reverse stock split at a ratio of 1-for-17 on March 7, 2025. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 01:14 UTC | Valion Bio, Inc. TIVC · Entity 8459 | Exercise / conversionCommon Stock | 92 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-26-002034 · ownership.xml · nonDerivative · entry 1 Wolf Lisa G · CIK 0001861556 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit is convertible into one share of Common Stock. F2 · balance_after: These numbers have been adjusted to reflect the reverse stock split of the common stock of Tivic Health Systems, Inc., which underwent a reverse stock split at a ratio of 1-for-17 on March 7, 2025. Read SEC document |
| December 18, 2025 Filed Dec 23, 2025 01:45 UTC | Valion Bio, Inc. TIVC · Entity 8459 | Exercise / conversionRestricted Stock Units · Derivative | 736 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-25-009306 · ownership.xml · derivative · entry 3 Wolf Lisa G · CIK 0001861556 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 735 Underlying: Common Stock · 736 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit is convertible into one share of Common Stock. F3 · derivative.exercise_date: Fifty percent (50%) of the Restricted Stock Units will vest upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: Fifty percent (50%) of the Restricted Stock Units will vest upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date. Read SEC document |
| December 18, 2025 Filed Dec 23, 2025 01:45 UTC | Valion Bio, Inc. TIVC · Entity 8459 | Tax withholdingCommon Stock | 302 | $1.87 | $564.74 |
DisclosureSEC source: 0001683168-25-009306 · ownership.xml · nonDerivative · entry 2 Wolf Lisa G · CIK 0001861556 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434 F2 · kind: The Reporting Person forfeited 302 shares of Common Stock upon vesting and settlement of 736 outstanding Restricted Stock Units to cover tax withholdings, using the market price of the Issuer's common stock at the time of forfeiture. Read SEC document |
| December 18, 2025 Filed Dec 23, 2025 01:45 UTC | Valion Bio, Inc. TIVC · Entity 8459 | Exercise / conversionCommon Stock | 736 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-25-009306 · ownership.xml · nonDerivative · entry 1 Wolf Lisa G · CIK 0001861556 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 736 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit is convertible into one share of Common Stock. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 22:46 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantEmployee Stock Option (Right to Purchase) · Derivative | 80,000 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001683168-25-005836 · ownership.xml · derivative · entry 1 Wolf Lisa G · CIK 0001861556 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-08-05 F1 · derivative.exercise_date: The stock option vests as follows: (i) 50% upon the first anniversary of the grant date, and (ii) the remaining 50% in a series of twelve (12) successive equal quarterly installments, rounded downward to the nearest whole share, measured from the first anniversary of the grant date, such that 100% of the stock option will be vested upon the fourth anniversary of the grant date. Read SEC document |
| August 06, 2025 Filed Aug 23, 2025 00:00 UTC Amendment | Valion Bio, Inc. TIVC · Entity 8459 | GrantEmployee Stock Option (Right to Purchase) · Derivative | 80,000 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001683168-25-006430 · ownership.xml · derivative · entry 1 Wolf Lisa G · CIK 0001861556 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-08-05 F1 · derivative.exercise_date: This Amendment No. 1 ("Form 4/A") to the Form 4 filed by the reporting person on August 8, 2025 (the "Original Form 4") is being filed to correct an administrative error, resulting in the incorrect vesting schedule for the stock option being included in the Original Form 4. As reflected in this Form 4/A, the stock option vests as follows: (i) 25% upon the first anniversary of the grant date, and (ii) the remaining 75% in a series of twelve (12) successive equal quarterly installments, rounded downward to the nearest whole share, measured from the first anniversary of the grant date, such that 100% of the stock option will be vested upon the fourth anniversary of the grant date. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 22:15 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-24-008899 · ownership.xml · derivative · entry 1 Wolf Lisa G · CIK 0001861556 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-12-17 F1 · derivative.exercise_price: Each Restricted Stock Unit is convertible into one share of Common Stock. F2 · derivative.exercise_date: Fifty percent (50%) of the Restricted Stock Units will vest upon the one (1) year anniversary of the Vesting Commencement Date, and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date. Read SEC document |
| March 28, 2022 Filed Mar 28, 2022 15:11 UTC | Resonant Inc RESN · Entity 128713 | Disposition to issuerRestricted Stock Units · Derivative | 53,244 | $4.50 | $239,598.00 |
DisclosureSEC source: 0001104659-22-038523 · tm2210529-8_4seq1.xml · derivative · entry 12 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 53,244 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Resonant Inc. common stock. F8 · derivative.exercise_date: In connection with the Merger Agreement, these restricted stock units, which provided for vesting of 13,111 shares on each of December 1, 2022, December 1, 2023, December 1, 2024, and December 1, 2025, were assumed and converted into a right of the holder to receive upon settlement an amount in cash equal to the per share merger consideration of $4.50 multiplied by the number of shares of common stock subject to such restricted stock units immediately prior to the merger. Upon the termination of the holder's employment with Resonant Inc. immediately following consummation of the merger, these assumed restricted stock units became fully vested and will be settled in cash. F8 · derivative.expiration_date: In connection with the Merger Agreement, these restricted stock units, which provided for vesting of 13,111 shares on each of December 1, 2022, December 1, 2023, December 1, 2024, and December 1, 2025, were assumed and converted into a right of the holder to receive upon settlement an amount in cash equal to the per share merger consideration of $4.50 multiplied by the number of shares of common stock subject to such restricted stock units immediately prior to the merger. Upon the termination of the holder's employment with Resonant Inc. immediately following consummation of the merger, these assumed restricted stock units became fully vested and will be settled in cash. Read SEC document |
| March 28, 2022 Filed Mar 28, 2022 15:11 UTC | Resonant Inc RESN · Entity 128713 | Disposition to issuerRestricted Stock Units · Derivative | 25,000 | $4.50 | $112,500.00 |
DisclosureSEC source: 0001104659-22-038523 · tm2210529-8_4seq1.xml · derivative · entry 11 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Resonant Inc. common stock. F7 · derivative.exercise_date: In connection with the Merger Agreement, these restricted stock units, which provided for vesting of 12,500 shares on each of December 1, 2022 and December 1, 2023, were assumed and converted into a right of the holder to receive upon settlement an amount in cash equal to the per share merger consideration of $4.50 multiplied by the number of shares of common stock subject to such restricted stock units immediately prior to the merger. Upon the termination of the holder's employment with Resonant Inc. immediately following consummation of the merger, these assumed restricted stock units became fully vested and will be settled in cash. F7 · derivative.expiration_date: In connection with the Merger Agreement, these restricted stock units, which provided for vesting of 12,500 shares on each of December 1, 2022 and December 1, 2023, were assumed and converted into a right of the holder to receive upon settlement an amount in cash equal to the per share merger consideration of $4.50 multiplied by the number of shares of common stock subject to such restricted stock units immediately prior to the merger. Upon the termination of the holder's employment with Resonant Inc. immediately following consummation of the merger, these assumed restricted stock units became fully vested and will be settled in cash. Read SEC document |
| March 28, 2022 Filed Mar 28, 2022 15:11 UTC | Resonant Inc RESN · Entity 128713 | Disposition to issuerRestricted Stock Units · Derivative | 29,577 | $4.50 | $133,096.50 |
DisclosureSEC source: 0001104659-22-038523 · tm2210529-8_4seq1.xml · derivative · entry 10 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,577 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Resonant Inc. common stock. F6 · derivative.exercise_date: In connection with the Merger Agreement, these restricted stock units, which provided for vesting of 9,859 shares on each of December 1, 2022, December 1, 2023, and December 1, 2024, were assumed and converted into a right of the holder to receive upon settlement an amount in cash equal to the per share merger consideration of $4.50 multiplied by the number of shares of common stock subject to such restricted stock units immediately prior to the merger. Upon the termination of the holder's employment with Resonant Inc. immediately following consummation of the merger, these assumed restricted stock units became fully vested and will be settled in cash. F6 · derivative.expiration_date: In connection with the Merger Agreement, these restricted stock units, which provided for vesting of 9,859 shares on each of December 1, 2022, December 1, 2023, and December 1, 2024, were assumed and converted into a right of the holder to receive upon settlement an amount in cash equal to the per share merger consideration of $4.50 multiplied by the number of shares of common stock subject to such restricted stock units immediately prior to the merger. Upon the termination of the holder's employment with Resonant Inc. immediately following consummation of the merger, these assumed restricted stock units became fully vested and will be settled in cash. Read SEC document |
| March 28, 2022 Filed Mar 28, 2022 15:11 UTC | Resonant Inc RESN · Entity 128713 | Disposition to issuerRestricted Stock Units · Derivative | 20,787 | $4.50 | $93,541.50 |
DisclosureSEC source: 0001104659-22-038523 · tm2210529-8_4seq1.xml · derivative · entry 9 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,787 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Resonant Inc. common stock. F5 · derivative.exercise_date: In connection with the Merger Agreement, these restricted stock units, which provided for vesting of 10,394 shares on December 1, 2022 and 10,393 shares on December 1, 2023, were assumed and converted into a right of the holder to receive upon settlement an amount in cash equal to the per share merger consideration of $4.50 multiplied by the number of shares of common stock subject to such restricted stock units immediately prior to the merger. Upon the termination of the holder's employment with Resonant Inc. immediately following consummation of the merger, these assumed restricted stock units became fully vested and will be settled in cash. F5 · derivative.expiration_date: In connection with the Merger Agreement, these restricted stock units, which provided for vesting of 10,394 shares on December 1, 2022 and 10,393 shares on December 1, 2023, were assumed and converted into a right of the holder to receive upon settlement an amount in cash equal to the per share merger consideration of $4.50 multiplied by the number of shares of common stock subject to such restricted stock units immediately prior to the merger. Upon the termination of the holder's employment with Resonant Inc. immediately following consummation of the merger, these assumed restricted stock units became fully vested and will be settled in cash. Read SEC document |
| March 28, 2022 Filed Mar 28, 2022 15:11 UTC | Resonant Inc RESN · Entity 128713 | Disposition to issuerRestricted Stock Units · Derivative | 6,931 | $4.50 | $31,189.50 |
DisclosureSEC source: 0001104659-22-038523 · tm2210529-8_4seq1.xml · derivative · entry 8 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,931 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Resonant Inc. common stock. F4 · derivative.exercise_date: In connection with the Merger Agreement, these restricted stock units, which provided for vesting on December 1, 2022, were assumed and converted into a right of the holder to receive upon settlement an amount in cash equal to the per share merger consideration of $4.50 multiplied by the number of shares of common stock subject to such restricted stock units immediately prior to the merger. Upon the termination of the holder's employment with Resonant Inc. immediately following consummation of the merger, these assumed restricted stock units became fully vested and will be settled in cash. F4 · derivative.expiration_date: In connection with the Merger Agreement, these restricted stock units, which provided for vesting on December 1, 2022, were assumed and converted into a right of the holder to receive upon settlement an amount in cash equal to the per share merger consideration of $4.50 multiplied by the number of shares of common stock subject to such restricted stock units immediately prior to the merger. Upon the termination of the holder's employment with Resonant Inc. immediately following consummation of the merger, these assumed restricted stock units became fully vested and will be settled in cash. Read SEC document |
| March 28, 2022 Filed Mar 28, 2022 15:11 UTC | Resonant Inc RESN · Entity 128713 | Disposition to issuerStock Options (Right to Buy) · Derivative | 4,808 | Not disclosed Strike: $4.62 | Not disclosed |
DisclosureSEC source: 0001104659-22-038523 · tm2210529-8_4seq1.xml · derivative · entry 7 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,808 shares Expires 2027-11-06 F1 · price: In connection with the Agreement and Plan of Merger, dated February 14, 2022, by and among Murata Electronics North America, Inc., PJ Cosmos Acquisition Company, Inc. and Resonant Inc. (the "Merger Agreement"), this stock option, which is fully vested, was cancelled in the merger. F1 · derivative.exercise_date: In connection with the Agreement and Plan of Merger, dated February 14, 2022, by and among Murata Electronics North America, Inc., PJ Cosmos Acquisition Company, Inc. and Resonant Inc. (the "Merger Agreement"), this stock option, which is fully vested, was cancelled in the merger. Read SEC document |
| March 28, 2022 Filed Mar 28, 2022 15:11 UTC | Resonant Inc RESN · Entity 128713 | Disposition to issuerStock Options (Right to Buy) · Derivative | 6,688 | Not disclosed Strike: $4.51 | Not disclosed |
DisclosureSEC source: 0001104659-22-038523 · tm2210529-8_4seq1.xml · derivative · entry 6 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,688 shares Expires 2027-08-07 F1 · price: In connection with the Agreement and Plan of Merger, dated February 14, 2022, by and among Murata Electronics North America, Inc., PJ Cosmos Acquisition Company, Inc. and Resonant Inc. (the "Merger Agreement"), this stock option, which is fully vested, was cancelled in the merger. F1 · derivative.exercise_date: In connection with the Agreement and Plan of Merger, dated February 14, 2022, by and among Murata Electronics North America, Inc., PJ Cosmos Acquisition Company, Inc. and Resonant Inc. (the "Merger Agreement"), this stock option, which is fully vested, was cancelled in the merger. Read SEC document |
| March 28, 2022 Filed Mar 28, 2022 15:11 UTC | Resonant Inc RESN · Entity 128713 | Disposition to issuerStock Options (Right to Buy) · Derivative | 15,319 | Not disclosed Strike: $4.36 | Not disclosed |
DisclosureSEC source: 0001104659-22-038523 · tm2210529-8_4seq1.xml · derivative · entry 5 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,319 shares Expires 2027-02-02 F2 · price: In connection with the Merger Agreement, this stock option, which is fully vested, was assumed and converted into a right of the holder to receive, no later than the first payroll date that occurs at least five business days after the closing of the merger, an amount in cash equal to the excess of the per share merger consideration of $4.50 over the exercise price per share of the common stock subject to the stock option multiplied by the total number of shares of common stock subject to such stock option immediately prior to the merger. F2 · derivative.exercise_date: In connection with the Merger Agreement, this stock option, which is fully vested, was assumed and converted into a right of the holder to receive, no later than the first payroll date that occurs at least five business days after the closing of the merger, an amount in cash equal to the excess of the per share merger consideration of $4.50 over the exercise price per share of the common stock subject to the stock option multiplied by the total number of shares of common stock subject to such stock option immediately prior to the merger. Read SEC document |
| March 28, 2022 Filed Mar 28, 2022 15:11 UTC | Resonant Inc RESN · Entity 128713 | Disposition to issuerStock Options (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $5.07 | Not disclosed |
DisclosureSEC source: 0001104659-22-038523 · tm2210529-8_4seq1.xml · derivative · entry 4 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2026-08-08 F1 · price: In connection with the Agreement and Plan of Merger, dated February 14, 2022, by and among Murata Electronics North America, Inc., PJ Cosmos Acquisition Company, Inc. and Resonant Inc. (the "Merger Agreement"), this stock option, which is fully vested, was cancelled in the merger. F1 · derivative.exercise_date: In connection with the Agreement and Plan of Merger, dated February 14, 2022, by and among Murata Electronics North America, Inc., PJ Cosmos Acquisition Company, Inc. and Resonant Inc. (the "Merger Agreement"), this stock option, which is fully vested, was cancelled in the merger. Read SEC document |
| March 28, 2022 Filed Mar 28, 2022 15:11 UTC | Resonant Inc RESN · Entity 128713 | Disposition to issuerStock Options (Right to Buy) · Derivative | 5,000 | Not disclosed Strike: $7.20 | Not disclosed |
DisclosureSEC source: 0001104659-22-038523 · tm2210529-8_4seq1.xml · derivative · entry 3 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2024-06-30 F1 · price: In connection with the Agreement and Plan of Merger, dated February 14, 2022, by and among Murata Electronics North America, Inc., PJ Cosmos Acquisition Company, Inc. and Resonant Inc. (the "Merger Agreement"), this stock option, which is fully vested, was cancelled in the merger. F1 · derivative.exercise_date: In connection with the Agreement and Plan of Merger, dated February 14, 2022, by and among Murata Electronics North America, Inc., PJ Cosmos Acquisition Company, Inc. and Resonant Inc. (the "Merger Agreement"), this stock option, which is fully vested, was cancelled in the merger. Read SEC document |
| March 28, 2022 Filed Mar 28, 2022 15:11 UTC | Resonant Inc RESN · Entity 128713 | OtherCommon Stock | 40 | $4.50 | $180.00 |
DisclosureSEC source: 0001104659-22-038523 · tm2210529-8_4seq1.xml · nonDerivative · entry 2 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Ms. Wolf's daughter Disclosed balance after: 0 Read SEC document |
| March 28, 2022 Filed Mar 28, 2022 15:11 UTC | Resonant Inc RESN · Entity 128713 | OtherCommon Stock | 170,568 | $4.50 | $767,556.00 |
DisclosureSEC source: 0001104659-22-038523 · tm2210529-8_4seq1.xml · nonDerivative · entry 1 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 23:39 UTC | Resonant Inc RESN · Entity 128713 | GrantRestricted Stock Units · Derivative | 53,244 | $0.00 | $0.00 |
DisclosureSEC source: 0001861556-22-000001 · primary_doc.xml · derivative · entry 1 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,244 Underlying: Common Stock · 53,244 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Resonant Inc. common stock. F2 · derivative.exercise_date: The restricted stock units will vest in four installments of 13,311 shares on each of December 1, 2022, December 1, 2023 and December 1, 2024, and December 1, 2025. F2 · derivative.expiration_date: The restricted stock units will vest in four installments of 13,311 shares on each of December 1, 2022, December 1, 2023 and December 1, 2024, and December 1, 2025. Read SEC document |
| December 03, 2021 Filed Dec 4, 2021 02:12 UTC | Resonant Inc RESN · Entity 128713 | SaleCommon Stock | 7,110 | $1.75 | $12,428.28 |
DisclosureSEC source: 0001861556-21-000008 · primary_doc.xml · nonDerivative · entry 6 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,568 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $1.73 to $1.78. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 02, 2021 Filed Dec 4, 2021 02:12 UTC | Resonant Inc RESN · Entity 128713 | SaleCommon Stock | 10,749 | $1.90 | $20,403.75 |
DisclosureSEC source: 0001861556-21-000008 · primary_doc.xml · nonDerivative · entry 5 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,678 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $1.88 to $1.9150. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 02:12 UTC | Resonant Inc RESN · Entity 128713 | Exercise / conversionRestricted Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001861556-21-000008 · primary_doc.xml · derivative · entry 11 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Resonant Inc. common stock. F8 · derivative.exercise_date: 12,500 restricted stock units vested on December 1, 2021, and installments of 12,500 restricted stock units will vest on each of December 1, 2022 and December 1, 2023. F8 · derivative.expiration_date: 12,500 restricted stock units vested on December 1, 2021, and installments of 12,500 restricted stock units will vest on each of December 1, 2022 and December 1, 2023. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 02:12 UTC | Resonant Inc RESN · Entity 128713 | Exercise / conversionRestricted Stock Units · Derivative | 9,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001861556-21-000008 · primary_doc.xml · derivative · entry 10 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,577 Underlying: Common Stock · 9,861 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Resonant Inc. common stock. F7 · derivative.exercise_date: 9,861 restricted stock units vested on December 1, 2021, and installments of 9,859 restricted stock units will vest on each of December 1, 2022, December 1, 2023 and December 1, 2024. F7 · derivative.expiration_date: 9,861 restricted stock units vested on December 1, 2021, and installments of 9,859 restricted stock units will vest on each of December 1, 2022, December 1, 2023 and December 1, 2024. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 02:12 UTC | Resonant Inc RESN · Entity 128713 | Exercise / conversionRestricted Stock Units · Derivative | 10,394 | $0.00 | $0.00 |
DisclosureSEC source: 0001861556-21-000008 · primary_doc.xml · derivative · entry 9 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,787 Underlying: Common Stock · 10,394 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Resonant Inc. common stock. F6 · derivative.exercise_date: 10,394 restricted stock units vested on December 1, 2021, an installment of 10,394 restricted stock units will vest on December 1, 2022, and an installment of 10,393 restricted stock units will vest on December 1, 2023. F6 · derivative.expiration_date: 10,394 restricted stock units vested on December 1, 2021, an installment of 10,394 restricted stock units will vest on December 1, 2022, and an installment of 10,393 restricted stock units will vest on December 1, 2023. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 02:12 UTC | Resonant Inc RESN · Entity 128713 | Exercise / conversionRestricted Stock Units · Derivative | 6,931 | $0.00 | $0.00 |
DisclosureSEC source: 0001861556-21-000008 · primary_doc.xml · derivative · entry 8 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,931 Underlying: Common Stock · 6,931 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Resonant Inc. common stock. F5 · derivative.exercise_date: 6,931 restricted stock units vested on December 1, 2021, and an installment of 6,391 restricted stock units will vest on December 1, 2022. F5 · derivative.expiration_date: 6,931 restricted stock units vested on December 1, 2021, and an installment of 6,391 restricted stock units will vest on December 1, 2022. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 02:12 UTC | Resonant Inc RESN · Entity 128713 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001861556-21-000008 · primary_doc.xml · nonDerivative · entry 4 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Resonant Inc. common stock. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 02:12 UTC | Resonant Inc RESN · Entity 128713 | Exercise / conversionCommon Stock | 9,861 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001861556-21-000008 · primary_doc.xml · nonDerivative · entry 3 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Resonant Inc. common stock. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 02:12 UTC | Resonant Inc RESN · Entity 128713 | Exercise / conversionCommon Stock | 10,394 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001861556-21-000008 · primary_doc.xml · nonDerivative · entry 2 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Resonant Inc. common stock. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 02:12 UTC | Resonant Inc RESN · Entity 128713 | Exercise / conversionCommon Stock | 6,931 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001861556-21-000008 · primary_doc.xml · nonDerivative · entry 1 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Resonant Inc. common stock. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 23:17 UTC | Resonant Inc RESN · Entity 128713 | SaleCommon Stock | 3,668 | $2.24 | $8,222.19 |
DisclosureSEC source: 0001861556-21-000007 · primary_doc.xml · nonDerivative · entry 2 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,741 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $2.21 to $2.29. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 23:17 UTC | Resonant Inc RESN · Entity 128713 | SaleCommon Stock | 1,234 | $2.35 | $2,900.76 |
DisclosureSEC source: 0001861556-21-000007 · primary_doc.xml · nonDerivative · entry 1 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,409 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.35 to $2.36. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 09, 2021 Filed Nov 13, 2021 02:06 UTC | Resonant Inc RESN · Entity 128713 | GrantCommon Stock | 10,598 | $0.00 | $0.00 |
DisclosureSEC source: 0001861556-21-000006 · primary_doc.xml · nonDerivative · entry 1 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,643 F1 · shares: Represents a grant of restricted stock units, 100% of which will vest on November 16, 2021. Read SEC document |
| August 18, 2021 Filed Aug 19, 2021 22:29 UTC | Resonant Inc RESN · Entity 128713 | SaleCommon Stock | 3,567 | $2.57 | $9,156.49 |
DisclosureSEC source: 0001861556-21-000005 · primary_doc.xml · nonDerivative · entry 1 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,045 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.5664 to $2.57. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 09, 2021 Filed Aug 12, 2021 00:52 UTC | Resonant Inc RESN · Entity 128713 | GrantCommon Stock | 6,346 | $0.00 | $0.00 |
DisclosureSEC source: 0001861556-21-000004 · primary_doc.xml · nonDerivative · entry 1 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,612 F1 · shares: Represents a grant of restricted stock units, 100% of which will vest on August 17, 2021. Read SEC document |
| May 19, 2021 Filed May 22, 2021 00:18 UTC | Resonant Inc RESN · Entity 128713 | SaleCommon Stock | 4,746 | $2.76 | $13,078.08 |
DisclosureSEC source: 0001861556-21-000003 · primary_doc.xml · nonDerivative · entry 1 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,266 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.75 to $2.76. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 14, 2021 Filed May 19, 2021 01:37 UTC | Resonant Inc RESN · Entity 128713 | SaleCommon Stock | 6,655 | $2.54 | $16,904.37 |
DisclosureSEC source: 0001861556-21-000002 · primary_doc.xml · nonDerivative · entry 1 Wolf Lisa G · CIK 0001861556 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,012 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.